ATTEST 2 aims to test tenecteplase in a large clinical trial to establish whether it is a better drug than alteplase for use in thrombolysis. This will involve a large number of hospitals in the UK, and possibly overseas. People who are considered suitable for thrombolysis will be allocated at random to receive either the current standard treatment with alteplase, or tenecteplase, and will be followed up for the first 90 days to measure the effects on recovery.
Even if there are no significant differences between between the two drugs, tenecteplase is less expensive and much easier to give to patients than alteplase, needing a single injection only. Alteplase has to be given as an injection followed by a longer injection over an hour. This advantage of tenecteplase alone would have worthwhile benefits to the patient.
Prospective Randomised Open, Blinded End-point (PROBE) – Phase III
Dr. Will Whitely, Stroke Medicine, University of Edinburgh & NHS Lothian
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax
This is a study looking at incidence and risk factors for poor ankle functional recovery, and the development and progression of post-traumatic ankle osteoarthritis after significant ankle ligament injury.
SALI study - Significant Ankle Ligament Injury